We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$12.1B
AUM Growth
+$1.27B
Cap. Flow
+$1.03B
Cap. Flow %
8.56%
Top 10 Hldgs %
10.66%
Holding
624
New
180
Increased
169
Reduced
84
Closed
163

Sector Composition

Rank Sector Weight
1 Technology 15.27%
2 Industrials 13.28%
3 Healthcare 12.87%
4 Consumer Discretionary 10.6%
5 Consumer Staples 10.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LN
401
DELISTED
LINE Corporation
LN
$1.7M 0.01%
50,000
ACGN
402
DELISTED
Aceragen Inc
ACGN
$1.64M 0.01%
8,031
+1,548
+24% +$369K
SNDX icon
403
Syndax Pharmaceuticals
SNDX
$1.82B
$1.61M 0.01%
225,000
+56,228
+33% +$616K
HDSN
404
Hudson Technologies
HDSN
$235M
$1.6M 0.01%
+200,000
New +$1.41M
FSTX
405
CALL
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.6M 0.01%
+50,000
New +$1.83M
FSTX
406
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.6M 0.01%
+50,000
New +$1.83M
DVN icon
407
Devon Energy
DVN
$47.3B
$1.57M 0.01%
34,399
-1,016,326
-97% -$44.9M
GPI icon
408
Group 1 Automotive
GPI
$3.18B
$1.54M 0.01%
19,752
-96,904
-83% -$6.66M
STAG icon
409
STAG Industrial
STAG
$7.19B
$1.47M 0.01%
+61,688
New +$1.42M
GATX icon
410
GATX Corp
GATX
$6.27B
$1.41M 0.01%
+22,941
New +$1.19M
AVGR
411
DELISTED
Avinger, Inc. Common Stock
AVGR
$1.41M 0.01%
3
SYRS
412
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.38M 0.01%
11,354
+90
+0.8% +$12.6K
CFRX
413
DELISTED
ContraFect Corporation
CFRX
$1.37M 0.01%
980
-116
-11% -$205K
LQ
414
DELISTED
La Quinta Holdings Inc.
LQ
$1.33M 0.01%
+93,842
New +$1.11M
ASC icon
415
Ardmore Shipping
ASC
$683M
$1.31M 0.01%
+176,678
New +$1.18M
MYOV
416
DELISTED
Myovant Sciences Ltd.
MYOV
$1.25M 0.01%
+100,404
New +$1.16M
RLGT icon
417
Radiant Logistics
RLGT
$395M
$1.23M 0.01%
316,168
-494,922
-61% -$1.6M
FLGT icon
418
Fulgent Genetics
FLGT
$527M
$1.18M 0.01%
102,185
-47,815
-32% -$451K
QTNA
419
DELISTED
Quantenna Communications, Inc. Common Stock
QTNA
$1.11M 0.01%
+61,126
New +$1.08M
ALIM
420
DELISTED
Alimera Sciences
ALIM
$1.09M 0.01%
67,593
+539
+0.8% +$9.87K
CDTX
421
DELISTED
Cidara Therapeutics
CDTX
$1.04M 0.01%
+5,000
New +$1.04M
VTVT icon
422
vTv Therapeutics
VTVT
$139M
$1.03M 0.01%
5,330
+1,283
+32% +$295K
CPAY icon
423
Corpay
CPAY
$25.7B
$1.02M 0.01%
+7,232
New +$1.13M
ARGS
424
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$980K 0.01%
10,000
WSC icon
425
CALL
WillScot Mobile Mini Holdings
WSC
$4.41B
$940K 0.01%
2,000,000

Similar funds

Alyeska Investment Group's Q4 2016 Portfolio in Review

As of Q4 2016, Alyeska Investment Group held 624 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Alyeska Investment Group deployed $1.03B of net new capital in Q4 2016, opening 180 new positions and adding to 169 existing holdings. Its largest new stake was Texas Instruments: 1,378,860 shares worth $101M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Palo Alto Networks, an estimated $120M trimmed.

  • Alyeska Investment Group's largest Q4 2016 buy was Texas Instruments: 1,378,860 shares worth $101M.
  • Alyeska Investment Group added most to Alphabet (Google) Class A in Q4 2016, an estimated $135M increase.
  • Alyeska Investment Group's biggest Q4 2016 reduction was Palo Alto Networks, cutting an estimated $120M.
  • Alyeska Investment Group fully exited Apple in Q4 2016, selling an estimated $217M.
  • Alyeska Investment Group's ten largest holdings make up 11% of its $12.1B portfolio in Q4 2016.
  • Alyeska Investment Group opened 180 new positions and closed 163 in Q4 2016.
  • Alyeska Investment Group's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.